HRP20191175T1 - Spojevi koji su inhibitori signaliziranja u notch putu - Google Patents
Spojevi koji su inhibitori signaliziranja u notch putu Download PDFInfo
- Publication number
- HRP20191175T1 HRP20191175T1 HRP20191175TT HRP20191175T HRP20191175T1 HR P20191175 T1 HRP20191175 T1 HR P20191175T1 HR P20191175T T HRP20191175T T HR P20191175TT HR P20191175 T HRP20191175 T HR P20191175T HR P20191175 T1 HRP20191175 T1 HR P20191175T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- cancer
- acceptable salt
- diastereomer
- intended
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 9
- 102000005650 Notch Receptors Human genes 0.000 title 1
- 108010070047 Notch Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 210000002266 hair cells auditory Anatomy 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- YDLRPJWRFYDKKP-SZQRVLIRSA-N 4,4,4-trifluoro-N-[(2S)-1-[(9-methoxy-3,3-dimethyl-5-oxo-2,6-dihydro-1H-pyrrolo[1,2-a][1]benzazepin-6-yl)amino]-1-oxopropan-2-yl]butanamide Chemical compound FC(CCC(=O)N[C@H](C(=O)NC1C(C=C2N(C3=C1C=CC(=C3)OC)CCC2(C)C)=O)C)(F)F YDLRPJWRFYDKKP-SZQRVLIRSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010011891 Deafness neurosensory Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- WWLBLCXYNQNMQE-WHUIICBVSA-N N-[(2S)-1-[(5,5-dimethyl-8-oxo-2,14-diazatricyclo[8.4.0.02,6]tetradeca-1(10),6,11,13-tetraen-9-yl)amino]-1-oxopropan-2-yl]-4,4,4-trifluorobutanamide Chemical compound CC1(CCN2C1=CC(C(C1=C2N=CC=C1)NC([C@H](C)NC(CCC(F)(F)F)=O)=O)=O)C WWLBLCXYNQNMQE-WHUIICBVSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Claims (8)
1. Spoj, naznačen time što ima strukturu:
,
4,4,4-trifluor-N-((2S)-1-((9-metoksi-3,3-dimetil-5-okso-2,3,5,6-tetrahidro-1H-benzo[f]pirolo[1,2-a]azepin-6-il)amino)-1-oksopropan-2-il)butanamid, njegov dijastereomerni izomer izomerne čistoće na položaju 6 veće od 90% enantiomernog viška, ili farmaceutski prihvatljiva sol bilo kojeg od gore navedenog.
2. Spoj, naznačen time što ima strukturu:
,
N-((2S)-1-((8,8-dimetil-6-okso-6,8,9,10-tetrahidro-5H-pirido[3,2-f]pirolo[1,2-a]azepin-5-il)amino)-1-oksopropan-2-il)-4,4,4-trifluorbutanamid, njegov dijastereomerni izomer izomerne čistoće na položaju 5 veće od 90% enantiomernog viška, ili farmaceutski prihvatljiva sol bilo kojeg od gore navedenog.
3. Farmaceutski pripravak, naznačen time što sadrži bilo spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu.
4. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
5. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju akutne limfoblastične leukemije T-stanica, akutne limfoblastične leukemije, kronične limfoblastične leukemije, akutne mijelogene leukemije, kronične mijelogene leukemije, eritroleukemije, trostruko negativnog raka dojke, raka dojke, raka jajnika, melanoma, raka pluća, raka velikih stanica pluća, raka gušterače, glioblastoma, kolorektalnog rak, raka glave i vrata, raka vrata maternice, raka prostate, raka jetre, oral karcinoma pločastih stanica, raka kože, meduloblastoma, angiosarkoma, rabdomiosarkoma, liposarkoma, zloćudnog fibroznog histiocitoma, hepatocelularnog karcinoma, intrahepatičnog ili ekstrahepatičnog kolangiokarcinoma ili adenoidnog cističnog karcinoma.
6. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5 u liječenju raka pluća.
7. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju senzorineuralnog gubitka sluha uzrokovanog gubitkom slušnih vlasastih stanica.
8. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u induciranju generiranja slušnih vlasastih stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189393P | 2015-07-07 | 2015-07-07 | |
| EP16741742.7A EP3319967B1 (en) | 2015-07-07 | 2016-07-01 | Notch pathway signaling inhibitor compounds |
| PCT/US2016/040612 WO2017007702A1 (en) | 2015-07-07 | 2016-07-01 | Notch pathway signaling inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191175T1 true HRP20191175T1 (hr) | 2019-10-04 |
Family
ID=56507825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191175TT HRP20191175T1 (hr) | 2015-07-07 | 2019-06-28 | Spojevi koji su inhibitori signaliziranja u notch putu |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| KR20190024983A (ko) | 2016-06-29 | 2019-03-08 | 오토노미, 인코포레이티드 | 트리글리세라이드 귀 제제 및 이의 용도 |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| AU2018237987B2 (en) * | 2017-03-24 | 2021-01-21 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
| US11117932B2 (en) * | 2018-07-20 | 2021-09-14 | The Hong Kong Polytechnic University | Peptides for specific inhibition of Jag 1-Notch 1 pathway |
| MA53645A (fr) * | 2018-09-21 | 2021-12-29 | Novartis Ag | Composés d'isoxazole carboxamide et leurs utilisations |
| CA3114113A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions and methods related to otic therapeutic agents |
| US20220008433A1 (en) * | 2018-11-30 | 2022-01-13 | Massachusetts Eye And Ear Infirmary | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells |
| CN114340611A (zh) | 2019-04-08 | 2022-04-12 | 频率医疗公司 | 用于治疗听力损失的chir99021和丙戊酸的组合 |
| US20230118097A1 (en) * | 2020-01-22 | 2023-04-20 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
| WO2023200017A1 (en) * | 2022-04-11 | 2023-10-19 | Prism BioLab Co., Ltd. | Novel seven-membered ring-fused compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| CN101410378B (zh) | 2006-03-27 | 2012-12-05 | 霍夫曼-拉罗奇有限公司 | 作为γ分泌酶抑制剂的丙二酰胺衍生物 |
| CA2714370C (en) | 2008-02-07 | 2017-05-02 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh-1 expression |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| CA2743436C (en) | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| US9125894B2 (en) | 2010-10-06 | 2015-09-08 | Massachusetts Eye & Ear Infirmary | Methods for promoting reinnervation of auditory hair cells |
| JO3148B1 (ar) * | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
| WO2014039781A1 (en) * | 2012-09-07 | 2014-03-13 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| AU2013337422A1 (en) | 2012-11-02 | 2015-05-07 | Genesys Research Institute | Compositions and methods for auditory therapy |
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| JP6904612B2 (ja) * | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
-
2016
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/en active Active
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/en active Application Filing
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 CA CA2987431A patent/CA2987431C/en active Active
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 MX MX2017016555A patent/MX2017016555A/es active IP Right Grant
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/me unknown
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active IP Right Grant
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
- 2018-05-17 HK HK18106380.5A patent/HK1247187B/zh unknown
-
2019
- 2019-06-28 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191175T1 (hr) | Spojevi koji su inhibitori signaliziranja u notch putu | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| MX2021000781A (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| PH12015501661B1 (en) | Pyridone amides as modulators of sodium channels | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
| MX2021015250A (es) | Composiciones que contienen ibrutinib. | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2016009427A (es) | Formulaciones de pridopidina de liberacion modificada. | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| MX368728B (es) | Amidas de piperidina fusionadas como moduladores de canales de iones. | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| MX2018003685A (es) | Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento. | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| MX2021007142A (es) | Compuestos organicos. | |
| MX2009008039A (es) | Gamma lactamas substituidas como agentes terapeuticos. | |
| MX2015008292A (es) | Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| MX2017013201A (es) | Derivados de indol. | |
| WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
| HRP20230105T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti | |
| SG11201810308TA (en) | Oral tipepidine preparation |